108 related articles for article (PubMed ID: 34552099)
1. A Replication stress biomarker is associated with response to gemcitabine versus combined gemcitabine and ATR inhibitor therapy in ovarian cancer.
Konstantinopoulos PA; da Costa AABA; Gulhan D; Lee EK; Cheng SC; Hendrickson AEW; Kochupurakkal B; Kolin DL; Kohn EC; Liu JF; Stover EH; Curtis J; Tayob N; Polak M; Chowdhury D; Matulonis UA; Färkkilä A; D'Andrea AD; Shapiro GI
Nat Commun; 2021 Sep; 12(1):5574. PubMed ID: 34552099
[TBL] [Abstract][Full Text] [Related]
2. A phase 1b study evaluating the safety and preliminary efficacy of berzosertib in combination with gemcitabine in patients with advanced non-small cell lung cancer.
Plummer R; Dean E; Arkenau HT; Redfern C; Spira AI; Melear JM; Chung KY; Ferrer-Playan J; Goddemeier T; Locatelli G; Dong J; Fleuranceau-Morel P; Diaz-Padilla I; Shapiro GI
Lung Cancer; 2022 Jan; 163():19-26. PubMed ID: 34894455
[TBL] [Abstract][Full Text] [Related]
3. Camonsertib in DNA damage response-deficient advanced solid tumors: phase 1 trial results.
Yap TA; Fontana E; Lee EK; Spigel DR; Højgaard M; Lheureux S; Mettu NB; Carneiro BA; Carter L; Plummer R; Cote GM; Meric-Bernstam F; O'Connell J; Schonhoft JD; Wainszelbaum M; Fretland AJ; Manley P; Xu Y; Ulanet D; Rimkunas V; Zinda M; Koehler M; Silverman IM; Reis-Filho JS; Rosen E
Nat Med; 2023 Jun; 29(6):1400-1411. PubMed ID: 37277454
[TBL] [Abstract][Full Text] [Related]
4. The Search for Genomic Biomarkers of Response to Immunotherapy in Ovarian Cancer.
Al-Rawi DH; Rusk N; Friedman CF
Clin Cancer Res; 2023 May; 29(9):1645-1647. PubMed ID: 36826422
[TBL] [Abstract][Full Text] [Related]
5. Non-linear IV pharmacokinetics of the ATR inhibitor berzosertib (M6620) in mice.
Deppas JJ; Kiesel BF; Guo J; Parise RA; Clump DA; D'Argenio DZ; Bakkenist CJ; Beumer JH
Cancer Chemother Pharmacol; 2024 May; ():. PubMed ID: 38743253
[TBL] [Abstract][Full Text] [Related]
6. Randomized Phase II Study of Gemcitabine With or Without ATR Inhibitor Berzosertib in Platinum-Resistant Ovarian Cancer: Final Overall Survival and Biomarker Analyses.
Konstantinopoulos PA; Cheng SC; Lee EK; da Costa AABA; Gulhan D; Wahner Hendrickson AE; Kochupurakkal B; Kolin DL; Kohn EC; Liu JF; Penson RT; Stover EH; Curtis J; Sawyer H; Polak M; Chowdhury D; D'Andrea AD; Färkkilä A; Shapiro GI; Matulonis UA
JCO Precis Oncol; 2024 Apr; 8():e2300635. PubMed ID: 38635934
[TBL] [Abstract][Full Text] [Related]
7. The DNA Damage Response (DDR) landscape of endometrial cancer defines discrete disease subtypes and reveals therapeutic opportunities.
Zhang X; Joseph S; Wu D; Bowser JL; Vaziri C
NAR Cancer; 2024 Jun; 6(2):zcae015. PubMed ID: 38596432
[TBL] [Abstract][Full Text] [Related]
8. The CHK1 inhibitor prexasertib in BRCA wild-type platinum-resistant recurrent high-grade serous ovarian carcinoma: a phase 2 trial.
Giudice E; Huang TT; Nair JR; Zurcher G; McCoy A; Nousome D; Radke MR; Swisher EM; Lipkowitz S; Ibanez K; Donohue D; Malys T; Lee MJ; Redd B; Levy E; Rastogi S; Sato N; Trepel JB; Lee JM
Nat Commun; 2024 Mar; 15(1):2805. PubMed ID: 38555285
[TBL] [Abstract][Full Text] [Related]
9. Targeting ATR in patients with cancer.
Ngoi NYL; Pilié PG; McGrail DJ; Zimmermann M; Schlacher K; Yap TA
Nat Rev Clin Oncol; 2024 Apr; 21(4):278-293. PubMed ID: 38378898
[TBL] [Abstract][Full Text] [Related]
10. The ORFIUS complex regulates ORC2 localization at replication origins.
Yang Z; Mogre S; He R; Berdan EL; Ho Sui SJ; Hill SJ
NAR Cancer; 2024 Mar; 6(1):zcae003. PubMed ID: 38288445
[TBL] [Abstract][Full Text] [Related]
11. Key Proteins of Replication Stress Response and Cell Cycle Control as Cancer Therapy Targets.
Khamidullina AI; Abramenko YE; Bruter AV; Tatarskiy VV
Int J Mol Sci; 2024 Jan; 25(2):. PubMed ID: 38279263
[TBL] [Abstract][Full Text] [Related]
12. Mapping combinatorial drug effects to DNA damage response kinase inhibitors.
Zhang H; Kreis J; Schelhorn SE; Dahmen H; Grombacher T; Zühlsdorf M; Zenke FT; Guan Y
Nat Commun; 2023 Dec; 14(1):8310. PubMed ID: 38097586
[TBL] [Abstract][Full Text] [Related]
13. ATM deficiency confers specific therapeutic vulnerabilities in bladder cancer.
Zhou Y; Börcsök J; Adib E; Kamran SC; Neil AJ; Stawiski K; Freeman D; Stormoen DR; Sztupinszki Z; Samant A; Nassar A; Bekele RT; Hanlon T; Valentine H; Epstein I; Sharma B; Felt K; Abbosh P; Wu CL; Efstathiou JA; Miyamoto DT; Anderson W; Szallasi Z; Mouw KW
Sci Adv; 2023 Nov; 9(47):eadg2263. PubMed ID: 37992168
[TBL] [Abstract][Full Text] [Related]
14. Targeting ATR in Cancer Medicine.
Salguero C; Valladolid C; Robinson HMR; Smith GCM; Yap TA
Cancer Treat Res; 2023; 186():239-283. PubMed ID: 37978140
[TBL] [Abstract][Full Text] [Related]
15. IGF-1R targeting in cancer - does sub-cellular localization matter?
Soni UK; Jenny L; Hegde RS
J Exp Clin Cancer Res; 2023 Oct; 42(1):273. PubMed ID: 37858153
[TBL] [Abstract][Full Text] [Related]
16. The clinical challenges of homologous recombination proficiency in ovarian cancer: from intrinsic resistance to new treatment opportunities.
Zielli T; Labidi-Galy I; Del Grande M; Sessa C; Colombo I
Cancer Drug Resist; 2023; 6(3):499-516. PubMed ID: 37842243
[TBL] [Abstract][Full Text] [Related]
17. A Phase I Expansion Cohort Study Evaluating the Safety and Efficacy of the CHK1 Inhibitor LY2880070 with Low-dose Gemcitabine in Patients with Metastatic Pancreatic Adenocarcinoma.
Huffman BM; Feng H; Parmar K; Wang J; Kapner KS; Kochupurakkal B; Martignetti DB; Sadatrezaei G; Abrams TA; Biller LH; Giannakis M; Ng K; Patel AK; Perez KJ; Singh H; Rubinson DA; Schlechter BL; Andrews E; Hannigan AM; Dunwell S; Getchell Z; Raghavan S; Wolpin BM; Fortier C; D'Andrea AD; Aguirre AJ; Shapiro GI; Cleary JM
Clin Cancer Res; 2023 Dec; 29(24):5047-5056. PubMed ID: 37819936
[TBL] [Abstract][Full Text] [Related]
18. Treatment of Ovarian Cancer Beyond PARP Inhibition: Current and Future Options.
Garg V; Oza AM
Drugs; 2023 Oct; 83(15):1365-1385. PubMed ID: 37737434
[TBL] [Abstract][Full Text] [Related]
19. Replication stress and defective checkpoints make fallopian tube epithelial cells putative drivers of high-grade serous ovarian cancer.
Galhenage P; Zhou Y; Perry E; Loc B; Fietz K; Iyer S; Reinhardt F; Da Silva T; Botchkarev V; Chen J; Crum CP; Weinberg RA; Pathania S
Cell Rep; 2023 Oct; 42(10):113144. PubMed ID: 37729060
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
